$PSNL Cashflow Statement | Understand Stock

$PSNL

$15.88 +$0.03 (0.19%) Close

$PSNL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense
Depreciation and amortization
Noncash operating lease cost
Noncash gain related to liability
Tempus Warrants
Total noncash gain related to liability
Amortization of discount on short-term investments
Change in fair value of convertible preferred stock warrant liability
Noncash restructuring and other charges
Noncash lease impairment expense
Other
Changes in operating assets and liabilities
Accounts receivable
Inventories and other deferred costs
Prepaid expenses and other assets
Accounts payable
Accrued and other current liabilities
Contract liabilities
Operating lease liabilities
Other long-term liabilities
Net cash used in operating activities
Cash flows from investing activities:
Purchases of available-for-sale debt securities
Proceeds from maturities of available-for-sale debt securities
Proceeds from sales of available-for-sale debt securities
Purchases of property and equipment
Proceeds from sales of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from public offerings, net of underwriting discounts and commissions
Payments of costs related to public offerings
Proceeds from sales of common stock under ATM facility, net of commissions
Proceeds from issuance of Tempus Warrants
Tempus Warrants
Total proceeds from issuance of Tempus Warrants
Proceeds from exercise of Tempus Warrants
Proceeds from sale of common stock under Tempus Investment Agreement
Proceeds from sale of common stock under Merck Investment Agreement
Payment of costs related to Tempus and Merck Investment Agreements
Proceeds from loans
Repayments of loans
Proceeds from exercise of equity awards
Proceeds from issuance of common stock under equity incentive plans
Net cash provided by financing activities

Effect of exchange rates on cash, cash equivalents and restricted cash
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental cash flow information:
Cash paid for income taxes, net of refunds
Acquisition of property and equipment included in accounts payable and accrued liabilities
Finance lease assets obtained in exchange for finance lease liabilities
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:
Cash and cash equivalents
Restricted cash, included in other long-term assets

Comments